title: Rituximab monotherapy for splenic marginal zone lymphoma.
abstract: In this retrospective study, rituximab was found to be effective therapy in 10 of 11 patients with splenic marginal zone lymphoma, inducing prompt reduction in splenomegaly, improvement in blood counts in 9 patients and clearance of a pleural effusion in 1 patient. Median response duration was 21 months (range 4 to 37 months). Two patients who relapsed at 21 and 23 months responded to retreatment. Rituximab should be considered in patients who are poor candidates for splenectomy.
authors.forename: Michael
authors.initials: M
authors.lastname: Bennett
authors.forename: Kumud
authors.initials: K
authors.lastname: Sharma
authors.forename: Shaiy
authors.initials: S
authors.lastname: Yegena
authors.forename: Israel
authors.initials: I
authors.lastname: Gavish
authors.forename: Harish P
authors.initials: HP
authors.lastname: Dave
authors.forename: Geraldine P
authors.initials: GP
authors.lastname: Schechter
mesh_terms: D000293:Adolescent; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010996:Pleural Effusion; D012008:Recurrence; D012189:Retrospective Studies; D000069283:Rituximab; D013154:Spleen / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab